Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $6.6 million.

  • Tango Therapeutics' Share-based Compensation fell 7.70% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year increase of 6.07%. This contributed to the annual value of $28.9 million for FY2024, which is 51.46% up from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Share-based Compensation is $6.6 million, which was up 0.84% from $6.6 million recorded in Q2 2025.
  • Tango Therapeutics' Share-based Compensation's 5-year high stood at $7.5 million during Q2 2024, with a 5-year trough of $950,000 in Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $6.6 million (2025), whereas its average is $6.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 720.57% in 2021, then dropped by 12.84% in 2025.
  • Over the past 5 years, Tango Therapeutics' Share-based Compensation (Quarterly) stood at $2.3 million in 2021, then surged by 67.70% to $3.8 million in 2022, then climbed by 28.90% to $4.9 million in 2023, then soared by 52.94% to $7.5 million in 2024, then declined by 7.70% to $6.6 million in 2025.
  • Its Share-based Compensation stands at $6.6 million for Q3 2025, versus $6.6 million for Q2 2025 and $7.3 million for Q1 2025.